Myosana has built a muscle-specific non-viral gene delivery platform designed to target muscle tissue with large gene capacity, enable repeat dosing, and avoid immune responses associated with viral vectors. The company’s lead therapeutic approach is delivery of full-length dystrophin as a potential therapy for Duchenne muscular dystrophy. Management says the platform could be applied across a broad range of neuromuscular and cardiac diseases to increase longevity and improve quality of life. Myosana plans to identify its first development candidate for Duchenne by 2025 and management has cited an 18–24 month timeline for candidate nomination tied to platform optimization. The company recently completed a seed financing of over $5 million to support those development activities. Myosana’s leadership includes cofounders Stan Froehner, Ph.D., and Nick Whitehead, Ph.D., and newly appointed CEO Dr. Matthew Lumley, a physician-scientist with experience in rare disease clinical development. Myosana Therapeutics is developing a pioneering non-viral gene delivery platform that specifically targets skeletal and cardiac muscle cells to deliver full-length genes, including dystrophin, regardless of gene size. The platform is intended to overcome limitations of AAV vectors such as micro-dystrophin delivery and immunogenicity. The company’s initial focus is on disease-modifying therapeutics for Duchenne muscular dystrophy, with potential applicability to other neuromuscular genetic diseases. Myosana will use the seed funding to advance development of its non-viral full-length dystrophin gene therapy. The company is a University of Washington spinout led by founders Stan Froehner and Nick Whitehead. As part of the transaction, CureDuchenne’s Debra Miller will join Myosana’s board.

Total raised

$6M

Funding rounds

2

Latest round

Seed

Latest activity

Jan 2023